Suppr超能文献

溶酶体酸性脂肪酶抑制剂 Lalistat-1 和 Lalistat-2 对中性脂肪水解酶的非靶标效应。

Off-target effects of the lysosomal acid lipase inhibitors Lalistat-1 and Lalistat-2 on neutral lipid hydrolases.

机构信息

Gottfried Schatz Research Center, Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.

Diagnostic and Research Institute of Pathology, Medical University Graz, Graz, Austria.

出版信息

Mol Metab. 2022 Jul;61:101510. doi: 10.1016/j.molmet.2022.101510. Epub 2022 Apr 30.

Abstract

OBJECTIVES

Lysosomal acid lipase (LAL) is the key enzyme, which degrades neutral lipids at an acidic pH in lysosomes. The role of LAL in various cellular processes has mostly been studied in LAL-knockout mice, which share phenotypical characteristics with humans suffering from LAL deficiency. In vitro, the cell-specific functions of LAL have been commonly investigated by using the LAL inhibitors Lalistat-1 and Lalistat-2.

METHODS

We performed lipid hydrolase activity assays and serine hydrolase-specific activity-based labeling combined with quantitative proteomics to investigate potential off-target effects of Lalistat-1 and -2.

RESULTS

Pharmacological LAL inhibition but not genetic loss of LAL impairs isoproterenol-stimulated lipolysis as well as neutral triglyceride and cholesteryl ester hydrolase activities. Apart from LAL, Lalistat-1 and -2 also inhibit major cytosolic lipid hydrolases responsible for lipid degradation in primary cells at neutral pH through off-target effects. Their binding to the active center of the enzymes leads to a decrease in neutral lipid hydrolase activities in cells overexpressing the respective enzymes.

CONCLUSIONS

Our findings are critically important since they demonstrate that commonly used concentrations of these inhibitors are not suitable to investigate the role of LAL-specific lipolysis in lysosomal function, signaling pathways, and autophagy. The interpretation of their effects on lipid metabolism should be taken with caution and the applied inhibitor concentrations in cell culture studies should not exceed 1 μM.

摘要

目的

溶酶体酸性脂肪酶(LAL)是一种关键酶,可在溶酶体的酸性 pH 下降解中性脂质。LAL 在各种细胞过程中的作用主要在 LAL 敲除小鼠中进行了研究,这些小鼠具有与 LAL 缺乏症患者相似的表型特征。在体外,通常使用 LAL 抑制剂 Lalistat-1 和 Lalistat-2 来研究 LAL 的细胞特异性功能。

方法

我们进行了脂质水解酶活性测定和丝氨酸水解酶特异性活性标记结合定量蛋白质组学,以研究 Lalistat-1 和 -2 的潜在非靶标效应。

结果

药理 LAL 抑制而不是 LAL 的遗传缺失会损害异丙肾上腺素刺激的脂肪分解以及中性甘油三酯和胆固醇酯水解酶活性。除了 LAL 之外,Lalistat-1 和 -2 还通过非靶标效应抑制主要的细胞质脂质水解酶,这些酶在中性 pH 下负责原代细胞中的脂质降解。它们与酶的活性中心结合会导致过表达相应酶的细胞中中性脂质水解酶活性降低。

结论

我们的发现非常重要,因为它们表明这些抑制剂的常用浓度不适合研究 LAL 特异性脂肪分解在溶酶体功能、信号通路和自噬中的作用。应谨慎解释它们对脂质代谢的影响,并且细胞培养研究中应用的抑制剂浓度不应超过 1μM。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验